Onconetix Inc
ONCO
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.5M
Close$
$1.39
232.1% upside
Current Fair Value
232.1% upsideUndervalued by 232.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.50 Million |
|---|---|
| Enterprise Value | $-4,256,907.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.73 |
| Beta | 2.61 |
| Outstanding Shares | 2,242,770 |
Return
| Return on Equity | -75.70% |
|---|---|
| Return on Assets | -62.07% |
| Return on Invested Capital | -62.43% |
Valuation & Multiples
| P/E Ratio | -0.05 |
|---|---|
| PEG | -0.23 |
| Price to Sales | - |
| Price to Book Ratio | 0.07 |
| Enterprise Value to Revenue | -6.59 |
| Enterprise Value to EBIT | 0.51 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.04 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 17, 2026
EPS Estimate
$-4505.00
Average shareholder expectationRevenue Estimate
$21,877
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-45050.00
Average shareholder expectationRevenue Estimate
$17,455
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.27%▲ 0.27% |
|---|---|
| Total Invested | $24,918 |
| Investors Holding | 5▲ 5.00% |
ESG Score
No data
About Onconetix Inc
3 employeesdeveloped by scientists at the prestigious oxford university in the uk, our vaccine protects against all influenza strains. it targets parts of the virus that are easy to induce a protective immune response against but also limited in...